Sagimet Biosciences, Ascletis BioScience, denifanstat, ASC40, FASN inhibitor, acne vulgaris, Phase 3 clinical trial, ASC40-304, ASC40-303, AURORA trial, dermatology,

FOSTER CITY, Calif. — October 9, 2026 Sagimet Biosciences Inc. announced positive full 52-week results from the Phase 3...